Potential prognostic value of PD-L1 and FOXP3 as predictors of relapse in breast cancer

Abstract

Background: Expression of PD-L1 detected by immunohistochemistry can represent a new hope for cancer management. The role of PD L1 in breast cancer is still unclear. Similarly, is the role of tumor-infiltrating FOXP3 +ve regulatory T (Treg) cells where literature data are conflicting. Our study aimed to evaluate the immunohistochemical expression of PD L1 and FOXP3 in breast cancer, correlate them with clinicopathological parameters as well as evaluating their relation.
Methods: This is a retrospective study carried out on 136 breast cancer specimens. Only cases with proved pathological diagnosis of infiltrating duct carcinoma of no special type (NST) were included. Tissue microarray blocks were constructed and immunostained with the polyclonal antibody for PDL1 and monoclonal antibody for FOXP3.
Results: Statistically significant correlation was found between high FOXP3 and nearly all adverse prognostic factors including; grade III tumors (p =.003), basal-like subtype(p =.001), high Ki67(p =.001), negative ER status(p =.001), negative PR(p =.028), HER2 expression(p =.04), advanced stage (p =.001), and LN metastases(p =.001). For PDL1, only statistically significant correlation with high Ki67 (p =.018) and advanced stage(p =.03) was found. A statistically significant positive correlation was found between PD L1 and FOXP3(p=.001). No statistically significant correlation was found between both PDL1 and FOXP3 in relation to disease-free survival (DFS) (p =.054). PDL1, age (≥ 50 years), nodal metastases were significant predictors of relapse in breast cancer.
Conclusion: The current study supports PDL1 as a predictor of relapse in breast cancer. Additionally, it highlights the synergistic role between PDL1 and FOXP3 in breast cancer microenvironment. Each can be considered as a poor prognostic marker in breast cancer. This raises a concern about the benefit of breast cancer patients from blocking of PDL1 pathway.

Keywords

Breast cancer / PDL1 / FOXP3 / Regulatory T cells

References

[1] Stanton SE, Disis ML. Clinical significance of tumor-infiltrating lymphocytes in breast cancer. Journal for Immunotherapy of Cancer. 2016; 4: 59. PMid:27777769. https://doi.org/10.1186/s40425-016-0165-6

[2] Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor immunity. Current Opin-ion in Immunology. 2012; 24(2): 207-12. PMid:22236695. https://doi.org/10.1016/j.coi.2011.12.009

[3] Reiss KA, Forde PM, Brahmer JR. Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promis-ing new anticancer strategy. Immunotherapy. 2014; 6(4): 459-75. PMid:24815784. https://doi.org/10.2217/imt.14.9

[4] Chen L, Deng H, Lu M, et al. B7-H 1 expression associates with tumor invasion and predicts patient’s survival in human esophageal cancer. International journal of clinical and experimental pathology. 2014; 7(9): 6015.

[5] Muenst S, Schaerli A, Gao F, et al. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast cancer research and treatment. 2014; 146(1):15-24. PMid:24842267. https://doi.org/10.1007/s10549-014-2988-5

[6] Frigola X, Inman BA, Lohse CM, et al. Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associ-ated with aggressive renal cell carcinoma. Clinical cancer research. 2011; 17(7): 1915-23. PMid:21355078. https://doi.org/10.1158/1078-0432.CCR-10-0250

[7] Zhou Z-J, Zhan P, Song Y. PD-L 1 over-expression and survival in pa-tients with non-small cell lung cancer: a meta-analysis. Translational lung cancer research. 2015; 4(2): 203.

[8] Wang Q, Lou W, Di W, et al. Prognostic value of tumor PD-L1 ex-pression combined with CD8(+) tumor infiltrating lymphocytes in high grade serous ovarian cancer. International immunopharmacol-ogy. 2017; 52: 7-14. PMid:28846888. https://doi.org/10.1016/j.intimp.2017.08.017

[9] Huang LJ, Deng XF, Chang F, et al. Prognostic significance of pro-grammed cell death ligand 1 expression in patients with ovarian carcinoma: A systematic review and meta-analysis. Medicine. 2018; 97(43). PMid:30412078. https://doi.org/10.1097/MD.0000000000012858

[10] Li Z, Dong P, Ren M, et al. PD-L 1 expression is associated with tumor FOXP3+ regulatory T-cell infiltration of breast cancer and poor prog-nosis of patient. Journal of Cancer. 2016; 7(7): 784. PMid:27162536. https://doi.org/10.7150/jca.14549

[11] Takenaka M, Seki N, Toh U, et al. FOXP 3 expression in tumor cells and tumor-infiltrating lymphocytes is associated with breast cancer prognosis. Molecular and Clinical Oncology. 2013; 1(4): 625-32. PMid:24649219. https://doi.org/10.3892/mco.2013.107

[12] Baptista MZ, Sarian LO, Derchain SF, et al. Prognostic significance of PD-L1 and PD-L2 in breast cancer. Human Pathology. 2016; 47(1):78-84. PMid:26541326. https://doi.org/10.1016/j.humpath.2015.09.006

[13] Muenst S, Schaerli AR, Gao F, et al. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2014; 146(1):15-24. PMid:24842267. https://doi.org/10.1007/s10549-014-2988-5

[14] Ren X, Wu H, Lu J, et al. PD1 protein expression in tumor infil-trated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer. Cancer Biology & Therapy. 2018; 19(5): 373-80. PMid:29336717. https://doi.org/10.1080/15384047.2018.1423919

[15] Beckers RK, Selinger CI, Vilain R, et al. Programmed death lig-and 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. Histopathol-ogy. 2016; 69(1): 25-34. PMid:26588661. https://doi.org/10.1111/his.12904

[16] Li S, Chen L, Jiang J. Role of programmed cell death ligand-1 expression on prognostic and overall survival of breast cancer: A systematic review and meta-analysis. Medicine (Baltimore). 2019; 98(16): e15201. PMid:31008945. https://doi.org/10.1097/MD.0000000000015201

[17] Wu Z, Zhang L, Peng J, et al. Predictive and prognostic value of PDL1 protein expression in breast cancer patients in neoadjuvant set-ting. Cancer biology & therapy. 2019; 20(6): 941-7. PMid:30866717. https://doi.org/10.1080/15384047.2019.1583533

[18] Noske A, Mobus V, Weber K, et al. Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study. European Journal of Cancer (Oxford, England: 1990). 2019; 114: 76-88. PMid:31075727. https://doi.org/10.1016/j.ejca.2019.04.010

[19] Schalper KA, Velcheti V, Carvajal D, et al. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better out-come in breast carcinomas. Clinical cancer research: an official journal of the American Association for Cancer Research. 2014; 20(10): 2773-82. PMid:24647569. https://doi.org/10.1158/1078-0432.CCR-13-2702

[20] Bertucci F, Finetti P, Birnbaum D, et al. The PD1/PDL 1 axis, a promising therapeutic target in aggressive breast cancers. On-coimmunology. 2016; 5(3): e1085148. PMid:27141340. https://doi.org/10.1080/2162402X.2015.1085148

[21] Ali HR, Glont SE, Blows FM, et al. PD-L 1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Annals of oncology : official journal of the European Society for Medical Oncology. 2015; 26(7): 1488-93. PMid:25897014. https://doi.org/10.1093/annonc/mdv192

[22] Liu F, Lang R, Zhao J, et al. CD8(+) cytotoxic T cell and FOXP3(+) regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res Treat. 2011; 130(2): 645-55. PMid:21717105. https://doi.org/10.1007/s10549-011-1647-3

[23] Kim ST, Jeong H, Woo OH, et al. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer. American journal of clinical oncology. 2013; 36(3): 224-31. PMid:22495453. https://doi.org/10.1097/COC.0b013e3182467d90

[24] Allaoui R, Hagerling C, Desmond E, et al. Infiltration of gammadelta T cells, IL-17+ T cells and FoxP3+ T cells in human breast cancer. Cancer biomarkers : section A of Disease markers. 2017; 20(4): 395-409. PMid:29060923. https://doi.org/10.3233/CBM-170026

[25] Glajcar A, Szpor J, Hodorowicz-Zaniewska D, et al. The composi-tion of T cell infiltrates varies in primary invasive breast cancer of different molecular subtypes as well as according to tumor size and nodal status. Virchows Archiv: an international journal of pathol-ogy. 2019. PMid:31016433. https://doi.org/10.1007/s00428-019-02568-y

[26] Yeong J, Thike AA, Lim JC, et al. Higher densities of Foxp3(+) regulatory T cells are associated with better prognosis in triple-negative breast cancer. Breast Cancer Res Treat. 2017; 163(1): 21-35. PMid:28233108. https://doi.org/10.1007/s10549-017-4161-4

[27] Park IH, Kong SY, Ro JY, et al. Prognostic Implications of Tumor- Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer. Clinical Breast Cancer. 2016; 16(1): 51-8. PMid:26364145. https://doi.org/10.1016/j.clbc.2015.07.006